ArticleNeurosurgical review2025
Stereotactic radiosurgery for subependymal giant cell astrocytoma: Multi-institutional retrospective analysis of clinical and radiological outcomes.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSubependymal giant cell astrocytomas (SEGAs) are benign tumors linked to tuberous sclerosis complex. Surgical resection remains the primary treatment, but carries risks of morbidity, particularly in cases of residual or recurrent disease. Stereotactic radiosurgery (SRS) offers a minimally invasive alternative, though evidence of its efficacy is unclear. This study presents a retrospective, multi-institutional analysis of SEGA outcomes after SRS.
methodsFourteen patients with histologically confirmed SEGA underwent Gamma Knife radiosurgery between 1998 and 2023 across seven centers of the International Radiosurgery Research Foundation. Demographics, tumor features, treatment parameters, and outcomes were evaluated. Local control (LC), progression-free survival (PFS), overall survival (OS), quality of life, and toxicity were analyzed.
resultsThe median age at treatment was 17 years, and all patients had prior surgery. Median radiological and clinical follow-up were 75 and 77.8 months. LC was achieved in 57.1% of cases, while 42.9% showed local failure, including one distant progression. PFS rates were 85.7% at 12 months and 71.4% at 24 months, with corresponding OS rates of 92.9% and 85.7%. No significant predictors of LC were identified. Post-SRS surgery was required in 35.8% due to progression. Treatment-related toxicity occurred in 21.4%, all Grade 1-2 and managed conservatively.
conclusionsSRS appears to be a safe option for patients with residual or recurrent SEGA who are unsuitable for further surgery. Despite modest LC rates, durable stabilization with minimal toxicity was achieved. Larger prospective studies are warranted to confirm these findings, optimize dosing and refine patient selection criteria.
Indexed as
Identifiers
41326850What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.